Imunon's Ovarian Cancer Trial Enrollment Exceeds Forecast, Completion Set for Q2 2029
IMNN is trading near its 52-week low of $1.47 (14% above the low) on light trading volume (0.4× avg).
Summary
Imunon's Phase 3 OVATION 3 trial for IMNN-001 in advanced ovarian cancer is enrolling faster than expected, with completion now projected for Q2 2029. The drug continues to show a favorable safety profile with no serious immune-related adverse events. This follows positive Phase 2 MRD data reported earlier this month and FDA alignment on the trial protocol in May. With a market cap of just $6.5M and a going concern warning, the strong enrollment signal is a critical de-risking event for the lead asset. The company's $10M June financing provides some runway, but the long timeline to data readout remains a key risk.
At the time of this announcement, IMNN was trading at $1.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.5M. The 52-week trading range was $1.47 to $8.19. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.